<DOC>
	<DOC>NCT00818753</DOC>
	<brief_summary>To assess whether two doses of dabigatran etexilate (110 mg twice daily (b.i.d) and 150 mg twice daily (b.i.d)) as compared to unfractionated heparin (UFH), both in addition to a standard dual antiplatelet regimen, provide sufficient anticoagulation in the setting of elective percutaneous coronary intervention (PCI).</brief_summary>
	<brief_title>Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Inclusion criteria: patients between 18 and 85 years due to undergo elective PCI informed consent obtained Exclusion criteria: PCI lesion specific conditions class III or IV congestive heart failure severe hypertension increased bleeding risk thrombolytic therapy within 24 hours preceding randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>